Boehringer Ingelheim and OSE Immunotherapeutics strike a collaboration deal

| By | Boehringer Ingelheim, Cancer Drugs, Drug Development

Boehringer Ingelheim, headquartered in Ingelheim, Germany, and OSE Immunotherapeutics, based in Nantes, Frances, signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.

OSE Immunotherapeutics is a biotechnology company focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases.

OSE-172 is a checkpoint inhibitor. It is a signal regulatory protein (SIRP)-alpha antagonist that targets myeloid lineage cells. SIRP-alpha is expressed by myeloid lineage cells like Dendritic Cells (DCs), tumor-associated macrophages (TAMs) and Myeloid-Derived Suppressor Cells (MDSCs). OSE-172 appears to prevent the activity of SIRP-alpha, which can improve the body’s immune response.

This is not the only partnership for OSE Immunotherapeutics. It has a development and commercialization program with Servier for its interleukin-7 antagonist that targets autoimmune disease. That deal is worth up to $283 million. It also has a research collaboration with Memorial Sloan Kettering to study OSE-703, an anti-CD127 antibody, for non-small cell lung cancer and other solid tumors. In July 2016, Johnson & Johnson’s Janssen optioned to license the company’s anti-CD28 monoclonal antibody, FR104, for autoimmune diseases.